Numerai’s Quest Diagnostics DGX Stock Holding History

Numerai’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Sell	6,196 -323	-5%	-$63.4K	0.11%	333
2026 Q1	$1.28M	Buy	+6,519	New	+$1.27M	0.13%	263

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Numerai's DGX Position: Q2 2026 in Review

Numerai reduced its Quest Diagnostics (DGX) stake by 5% in Q2 2026, selling an estimated $63.4K and leaving 6,196 shares worth $1.31M. The position accounts for 0.11% of the portfolio, ranked #333.

Numerai first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Numerai held 6,196 shares of Quest Diagnostics worth $1.31M as of Q2 2026.
Numerai sold 323 Quest Diagnostics shares in Q2 2026, an estimated $63.4K.
Quest Diagnostics made up 0.11% of Numerai's portfolio in Q2 2026, its #333 holding.
Numerai first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Numerai's 13F filing for Q2 2026, filed 14 Aug 2026.